Fig. 2

A1CF bound to FAM224A and strengthened its stability. a. The FAM224A expression of glioma cells treated with altering A1CF expression was showed. Data represent mean ± SD (n = 5, each group). ^**P < 0.01 vs. A1CF (+)-NC group (negative control); ^##P < 0.01 vs. A1CF (−)-NC group (negative control). b. FAM224A was confirmed in the A1CF complex. Data represent mean ± SD (n = 5, each group). ^**P < 0.01 vs. anti-IgG group. c. The remaining levels of FAM224A at the different time points treated with actinomycin D were indicated. d. Nascent RNA capture assay was used to evaluate the nascent FAM224A in A1CF (+) and A1CF (−) group. e-g. CCK-8 assay, flow cytometry analysis and migration and invasion assays were used to detected the impacts of A1CF and FAM224A knockdown on biological behaviors of glioma cells. Data are presented as the mean ± SD (n = 5, each group). ^**P < 0.01 vs. A1CF (−)-NC + FAM224 (−)-NC; ^##P < 0.01 vs. A1CF (−) + FAM224 (−)-NC; ^#P < 0.05 vs. A1CF (−) + FAM224 (−)-NC; ^&&P < 0.01 vs. A1CF (−)-NC + FAM224 (−) group. Scale bar of migration and invasion assays represent 40 μm